Connecticut Bioscience Industry Overview



May 6, 2021



Dedicated to the growth of a vibrant bioscience ecosystem, our organization connects companies, institutions, entrepreneurs, investors, government, service providers, and other passionate, dedicated people to improve patients' lives and public health.

ADVANCECT

AdvanceCT strives to build a place where business, government, higher education and nonprofits come together to implement high impact and inclusive economic development solutions to advance overall competitiveness in Connecticut.



Amtrak Acela line along Hwy 95 corridor where Bio/Pharma Clusters Live





Cost of Space

ASSET CLASS	CONNECTICUT	NEW YORK	MASSACHUSETTES	NEW JERSEY	PENNSYLVANIA

\$67.85

(Cambridge)

\$76.09

(Cambridge)

\$13.17

(North & Central)

\$31.64

\$9.29

(North)

(North &

@bioct_org | www.bioct.org

\$22.28

Central)

\$29.77

\$28.20

\$5.83

(Philadelphia)

(Philadelphia)

(Philadelphia)

\$73.91

(Manhattan)

\$79.93

(Manhattan)

Island)

(Long

\$9.81

CLASS A OFFICE SPACE

LAB

INDUSTRIAL


BioCT

\$41.33 (Stamford)

29.50 (New Haven)

\$5.51 (New Haven)

The evolution of a Bio CLUSTER





How is Connecticut organized and sustained?

- Pipelines of innovation and talent are economic drivers. Yale OCR Tech Transfer graduates approx. 30 companies/year, many with successful IPO's and significant growth within a 3-5 year timeline.
- Clusters continue to expand in proximity to Yale and UConn.
 Expansion is organic and largely result of new partnerships being formed with universities as well as intellectual property generated within the universities and serial entrepreneurs.
- Key academic centers of excellence include Yale, UConn, Jackson Laboratory along with Pfizer, Boehringer Ingelheim, Alexion, BioHaven, IsoPlexis, Medtronic, Sema4 and many others.



How is Connecticut organized and sustained?









abcam





TYALE







ARVINAS






















Route 34


















2020 Venture Investments in Connecticut

- 80 companies
- 85 deals
- 107 investors
- \$723.67M capital invested
- Average Raise \$8.5M
- Median Raise \$2.0M
- Median Post Valuation \$20.50M


































NEUROLOGY/ NEUROSCIENCE

















Allyx Therapeutics



bioasis











RARE DISEASES











Workforce Development

- SCSU BioPath program
- https://biopath.southernct.edu/



- BioCT Career Portal
- https://bioct.org/careers/overview/
- BioCT Professional Development Courses
- https://bioct.org/membership/member-resources/
- New Haven Works
- http://newhavenworkspipeline.org/





BioCT

What are predictions for the future?

- Continue to invest, grow sector with talent and capital to fuel economy recovery.
- R&D will continue to intersect with digital, med device and technology to drive innovation.
- Strong insurance, fintech, advanced manufacturing, academic and bio sector.
- Growth will continue in clusters such as:
 - New Haven and Greater New Haven-Yale anchor
 - Farmington with Jackson Laboratory and UConn/Incubator-TIP
 - Stamford/Fairfield County with tech space and finance
 - Hartford with med device, insurance
- Lab space in high demand and developers continue to explore solutions.
- New England Life Science is a growing region. CT is dynamically situated along the I-95 corridor between MA, CT, RI, NY, NJ where much collaboration is underway.
- CT is affordable, great quality of life, tremendous shoreline with a highly educated population/workforce and stellar academic institutions.
- <u>www.wheresciencelives.com</u> campaign



Arigatou Gozaimasu

Dawn Hocevar
President & CEO
BioCT
dhocevar@bioct.org



